Videos

15:52

Radiation therapy for breast cancer patients is examined in an interview with Dr. Michael Alvarado of the UCSF Comprehensive Cancer Center and Dr. Jay Harness, medical director at BreastCancerAnswers,com, at the 2012 San Antonio Breast Cancer Symposium. The live broadcast was sponsored by Genomic Health, the creator of Oncotype DX. Genomic Health is a global healthcare company that provides actionable genomic information to personalize cancer treatment decisions. For more information, please visit: www.genomichealth.com

4:23

In this video, Dr. Eric Winer, Director of the Breast Oncology Program and one of the leaders of the Susan F. Smith Center for Women's Cancers at Dana-Farber, shares the definition of DCIS, weighs in on whether or not DCIS is considered cancer, and describes treatment options for women with DCIS. Learn more about how Dana-Farber's physicians treat breast cancer at http://www.dana-farber.org/Adult-Care/Treatment-and-Support/Treatment-Ce....

at http://www.dana-farber.org/Adult-Care/Treatment-and-Support/Treatment-Ce....

0:39

Genomic Health's Senior Director of Pathology, Dr. Rick Baehner, says that DCIS breast cancer patients who have had a lumpectomy are eligible for the Oncotype DX DCIS Score.

0:40

Patients diagnosed with DCIS breast cancer can obtain an Oncotype DX DCIS Score, which is covered by Medicare, but reimbursement for private payers can vary. Genomic Health Senior Director of Pathology Dr. Rick Baehner explains that Genomic Health will work with DCIS breast cancer patients and their insurance companies to arrange coverage.

1:44

What is the likelihood of DCIS breast cancer coming back after treatment? Dr. Rick Baehner, Senior Director of Pathology at Genomic Health, talks about what DCIS breast cancer patients can expect in terms of percentages.

1:03

Genomic Health's Dr. Rick Baehner, Senior Director of Pathology, reviews the various treatment options for those diagnosed with DCIS breast cancer. The Oncotype DX DCIS Breast Cancer Assay and DCIS Score only apply to those breast cancer patients who have a lumpectomy.

1:32

Genomic Health Senior Director of Pathology Dr. Rick Baehner examines the benefits using the Oncotype DX DCIS Score over other tools that are currently being used to create DCIS breast cancer treatment decisions.

1:15

Dr. Rick Baehner, Senior Director of Pathology at Genomic Health, recounts a recent experience he had with a DCIS breast cancer patient.